TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases

Am J Hematol. 2021 Aug 1;96(8):E306-E310. doi: 10.1002/ajh.26235. Epub 2021 May 25.
No abstract available

Publication types

  • Letter
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chromosome Deletion
  • Chromosomes, Human, Pair 17
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / genetics*
  • Leukemia, Lymphocytic, Chronic, B-Cell / therapy*
  • Molecular Targeted Therapy
  • Mutation
  • Prognosis
  • Retrospective Studies
  • Risk Factors
  • Tumor Suppressor Protein p53 / genetics*

Substances

  • TP53 protein, human
  • Tumor Suppressor Protein p53